Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review

This review discusses the efficacy and safety in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) of intravenous immunoglobulin and compares this treatment with plasma exchange and prednisolone. We searched publications from 1985 onwards for randomised controlled studies examining th...

Full description

Saved in:
Bibliographic Details
Published in:Lancet neurology 2002-12, Vol.1 (8), p.491-498
Main Authors: van Schaik, Ivo N, Winer, John B, de Haan, Rob, Vermeulen, Marinus
Format: Article
Language:English
Subjects:
Algorithms
Anti-Inflammatory Agents - therapeutic use
Humans
Immunoglobulins, Intravenous - adverse effects
Immunoglobulins, Intravenous - therapeutic use
Plasma Exchange
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - drug therapy
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - physiopathology
Prednisolone - therapeutic use
Randomized Controlled Trials as Topic
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c388t-fde75d6771f7f6eb20b26ae736b365b6e2e2130151dd09b50a80090bcd329ca33
cites cdi_FETCH-LOGICAL-c388t-fde75d6771f7f6eb20b26ae736b365b6e2e2130151dd09b50a80090bcd329ca33
container_end_page 498
container_issue 8
container_start_page 491
container_title Lancet neurology
container_volume 1
creator van Schaik, Ivo N
Winer, John B
de Haan, Rob
Vermeulen, Marinus
description This review discusses the efficacy and safety in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) of intravenous immunoglobulin and compares this treatment with plasma exchange and prednisolone. We searched publications from 1985 onwards for randomised controlled studies examining the effects of intravenous immunoglobulin in patients with this immune-mediated neuromuscular disorder. Six trials, with 170 patients in total, were judged eligible. A significantly higher proportion of patients improved in disability within a month after the start of treatment with intravenous immunoglobulin than with placebo (relative risk 3·17 [95% CI 1·74 to 5·75]). During this period, intravenous immunoglobulin has similar efficacy to plasma exchange and oral prednisolone; therefore which of these treatments should be the first choice is currently uncertain. An algorithm on treatment approaches for CIDP is proposed.
doi_str_mv 10.1016/S1474-4422(02)00222-3
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72902658</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1474442202002223</els_id><sourcerecordid>72902658</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-fde75d6771f7f6eb20b26ae736b365b6e2e2130151dd09b50a80090bcd329ca33</originalsourceid><addsrcrecordid>eNqFkc1q3TAQhUVIyV_zCC0mi9IunIwkW7a7KSWkaSCQRdq1kKVxomBJt5Kd4Lev3HtJoZuCYIT4zmjmHELeUTinQMXFPa2aqqwqxj4C-wTAGCv5HjnaPYt6__XO2CE5TukpQ7Rq6QE5pKytOs6rI-Ju_BTVM_owp8I6N_vwMIZ-Hq0vhhAL_RiDt7qwfhiVc2oKcSkMugUzoSbrH4pNGJeojNXzGDzOMWzU9Lh8LlSRljRh1mR9xGeLL2_Jm0GNCU939YT8_Hb14_J7eXt3fXP59bbUvG2ncjDY1EY0DR2aQWDPoGdCYcNFz0XdC2TIKAdaU2Og62tQLUAHvTacdVpxfkI-bPtuYvg1Y5qks0njOCqPeVHZsA6YqNsMnv0DPoU5-jybZEArENCtUL2FdAwpRRzkJlqn4iIpyDUM-ScMuTotIZ81DLlO8X7XfO4dmr-qnfsZ-LIFMHuR_YkyaYteo7ER9SRNsP_54jdKkJvj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>201406098</pqid></control><display><type>article</type><title>Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review</title><source>Elsevier</source><creator>van Schaik, Ivo N ; Winer, John B ; de Haan, Rob ; Vermeulen, Marinus</creator><creatorcontrib>van Schaik, Ivo N ; Winer, John B ; de Haan, Rob ; Vermeulen, Marinus</creatorcontrib><description>This review discusses the efficacy and safety in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) of intravenous immunoglobulin and compares this treatment with plasma exchange and prednisolone. We searched publications from 1985 onwards for randomised controlled studies examining the effects of intravenous immunoglobulin in patients with this immune-mediated neuromuscular disorder. Six trials, with 170 patients in total, were judged eligible. A significantly higher proportion of patients improved in disability within a month after the start of treatment with intravenous immunoglobulin than with placebo (relative risk 3·17 [95% CI 1·74 to 5·75]). During this period, intravenous immunoglobulin has similar efficacy to plasma exchange and oral prednisolone; therefore which of these treatments should be the first choice is currently uncertain. An algorithm on treatment approaches for CIDP is proposed.</description><identifier>ISSN: 1474-4422</identifier><identifier>EISSN: 1474-4465</identifier><identifier>DOI: 10.1016/S1474-4422(02)00222-3</identifier><identifier>PMID: 12849334</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Algorithms ; Anti-Inflammatory Agents - therapeutic use ; Humans ; Immunoglobulins, Intravenous - adverse effects ; Immunoglobulins, Intravenous - therapeutic use ; Plasma Exchange ; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - drug therapy ; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - physiopathology ; Prednisolone - therapeutic use ; Randomized Controlled Trials as Topic ; Systematic review</subject><ispartof>Lancet neurology, 2002-12, Vol.1 (8), p.491-498</ispartof><rights>2002 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Dec 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c388t-fde75d6771f7f6eb20b26ae736b365b6e2e2130151dd09b50a80090bcd329ca33</citedby><cites>FETCH-LOGICAL-c388t-fde75d6771f7f6eb20b26ae736b365b6e2e2130151dd09b50a80090bcd329ca33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12849334$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van Schaik, Ivo N</creatorcontrib><creatorcontrib>Winer, John B</creatorcontrib><creatorcontrib>de Haan, Rob</creatorcontrib><creatorcontrib>Vermeulen, Marinus</creatorcontrib><title>Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review</title><title>Lancet neurology</title><addtitle>Lancet Neurol</addtitle><description>This review discusses the efficacy and safety in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) of intravenous immunoglobulin and compares this treatment with plasma exchange and prednisolone. We searched publications from 1985 onwards for randomised controlled studies examining the effects of intravenous immunoglobulin in patients with this immune-mediated neuromuscular disorder. Six trials, with 170 patients in total, were judged eligible. A significantly higher proportion of patients improved in disability within a month after the start of treatment with intravenous immunoglobulin than with placebo (relative risk 3·17 [95% CI 1·74 to 5·75]). During this period, intravenous immunoglobulin has similar efficacy to plasma exchange and oral prednisolone; therefore which of these treatments should be the first choice is currently uncertain. An algorithm on treatment approaches for CIDP is proposed.</description><subject>Algorithms</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Humans</subject><subject>Immunoglobulins, Intravenous - adverse effects</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Plasma Exchange</subject><subject>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - drug therapy</subject><subject>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - physiopathology</subject><subject>Prednisolone - therapeutic use</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Systematic review</subject><issn>1474-4422</issn><issn>1474-4465</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNqFkc1q3TAQhUVIyV_zCC0mi9IunIwkW7a7KSWkaSCQRdq1kKVxomBJt5Kd4Lev3HtJoZuCYIT4zmjmHELeUTinQMXFPa2aqqwqxj4C-wTAGCv5HjnaPYt6__XO2CE5TukpQ7Rq6QE5pKytOs6rI-Ju_BTVM_owp8I6N_vwMIZ-Hq0vhhAL_RiDt7qwfhiVc2oKcSkMugUzoSbrH4pNGJeojNXzGDzOMWzU9Lh8LlSRljRh1mR9xGeLL2_Jm0GNCU939YT8_Hb14_J7eXt3fXP59bbUvG2ncjDY1EY0DR2aQWDPoGdCYcNFz0XdC2TIKAdaU2Og62tQLUAHvTacdVpxfkI-bPtuYvg1Y5qks0njOCqPeVHZsA6YqNsMnv0DPoU5-jybZEArENCtUL2FdAwpRRzkJlqn4iIpyDUM-ScMuTotIZ81DLlO8X7XfO4dmr-qnfsZ-LIFMHuR_YkyaYteo7ER9SRNsP_54jdKkJvj</recordid><startdate>20021201</startdate><enddate>20021201</enddate><creator>van Schaik, Ivo N</creator><creator>Winer, John B</creator><creator>de Haan, Rob</creator><creator>Vermeulen, Marinus</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20021201</creationdate><title>Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review</title><author>van Schaik, Ivo N ; Winer, John B ; de Haan, Rob ; Vermeulen, Marinus</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-fde75d6771f7f6eb20b26ae736b365b6e2e2130151dd09b50a80090bcd329ca33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Algorithms</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Humans</topic><topic>Immunoglobulins, Intravenous - adverse effects</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Plasma Exchange</topic><topic>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - drug therapy</topic><topic>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - physiopathology</topic><topic>Prednisolone - therapeutic use</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van Schaik, Ivo N</creatorcontrib><creatorcontrib>Winer, John B</creatorcontrib><creatorcontrib>de Haan, Rob</creatorcontrib><creatorcontrib>Vermeulen, Marinus</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Lancet neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van Schaik, Ivo N</au><au>Winer, John B</au><au>de Haan, Rob</au><au>Vermeulen, Marinus</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review</atitle><jtitle>Lancet neurology</jtitle><addtitle>Lancet Neurol</addtitle><date>2002-12-01</date><risdate>2002</risdate><volume>1</volume><issue>8</issue><spage>491</spage><epage>498</epage><pages>491-498</pages><issn>1474-4422</issn><eissn>1474-4465</eissn><coden>LANCAO</coden><abstract>This review discusses the efficacy and safety in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) of intravenous immunoglobulin and compares this treatment with plasma exchange and prednisolone. We searched publications from 1985 onwards for randomised controlled studies examining the effects of intravenous immunoglobulin in patients with this immune-mediated neuromuscular disorder. Six trials, with 170 patients in total, were judged eligible. A significantly higher proportion of patients improved in disability within a month after the start of treatment with intravenous immunoglobulin than with placebo (relative risk 3·17 [95% CI 1·74 to 5·75]). During this period, intravenous immunoglobulin has similar efficacy to plasma exchange and oral prednisolone; therefore which of these treatments should be the first choice is currently uncertain. An algorithm on treatment approaches for CIDP is proposed.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>12849334</pmid><doi>10.1016/S1474-4422(02)00222-3</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1474-4422
ispartof Lancet neurology, 2002-12, Vol.1 (8), p.491-498
issn 1474-4422
1474-4465
language eng
recordid cdi_proquest_miscellaneous_72902658
source Elsevier
subjects Algorithms
Anti-Inflammatory Agents - therapeutic use
Humans
Immunoglobulins, Intravenous - adverse effects
Immunoglobulins, Intravenous - therapeutic use
Plasma Exchange
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - drug therapy
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - physiopathology
Prednisolone - therapeutic use
Randomized Controlled Trials as Topic
Systematic review
title Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T15%3A27%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravenous%20immunoglobulin%20for%20chronic%20inflammatory%20demyelinating%20polyradiculoneuropathy:%20a%20systematic%20review&rft.jtitle=Lancet%20neurology&rft.au=van%20Schaik,%20Ivo%20N&rft.date=2002-12-01&rft.volume=1&rft.issue=8&rft.spage=491&rft.epage=498&rft.pages=491-498&rft.issn=1474-4422&rft.eissn=1474-4465&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1474-4422(02)00222-3&rft_dat=%3Cproquest_cross%3E72902658%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c388t-fde75d6771f7f6eb20b26ae736b365b6e2e2130151dd09b50a80090bcd329ca33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=201406098&rft_id=info:pmid/12849334&rfr_iscdi=true